EXAS — Exact Sciences Cashflow Statement
0.000.00%
Last trade - 00:00
- $12.11bn
- $13.75bn
- $2.50bn
- 65
- 31
- 47
- 45
C2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -84 | -849 | -596 | -624 | -204 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 161 | 874 | 455 | 241 | 155 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -53.6 | -42.7 | 111 | -26.4 | -0.342 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -112 | 136 | -102 | -224 | 156 |
Capital Expenditures | -173 | -476 | -194 | -214 | -125 |
Purchase of Fixed Assets | |||||
Software Development Costs | |||||
Other Investing Cash Flow Items | 48.2 | -226 | -888 | 289 | 174 |
Acquisition of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -124 | -702 | -1,082 | 74.1 | 49.7 |
Financing Cash Flow Items | 7.95 | 15.3 | 17.8 | 20 | 18.6 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 253 | 1,880 | 8.47 | 76.5 | 160 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 17.1 | 1,314 | -1,176 | -73 | 367 |